Phase 2 Window Study of SAR439859 (Amcenestrant) Versus Letrozole in Post-menopausal Patients With ER+, HER2- Pre-operative Post-menopausal Primary Breast Cancer

Investigational Site Number 0560001, Leuven

Investigational Site Number 0560002, Namur

Investigational Site Number 7240003, Córdoba

Investigational Site Number 3800002, Milan

Investigational Site Number 3800001, Milan

Investigational Site Number 8040002, Vinnytsia

Investigational Site Number 8400016, Winston-Salem

Investigational Site Number 7240001, Madrid

Investigational Site Number 2500003, Toulouse

Investigational Site Number 2500001, Nantes

Investigational Site Number 7240002, Valencia

Investigational Site Number 8400018, Fort Wayne

Investigational Site Number 3800004, Meldola

Investigational Site Number 8040004, Kharkiv

Investigational Site Number 8400005, Lincoln

Investigational Site Number 8040005, Zaporizhzhya

Investigational Site Number 2500004, Paris

Investigational Site Number 8400014, Tucson

Investigational Site Number 8040001, Uzhhorod

Investigational Site Number 8400010, Los Angeles

Investigational Site Number 2500002, Saint-Cloud

Investigational Site Number 8400012, Tacoma

Investigational Site Number 6430006, Moscow

Investigational Site Number 6430004, Moscow

Investigational Site Number 6430003, Saint Petersburg

Investigational Site Number 6430007, Saint Petersburg

Investigational Site Number 6430002, Saint Petersburg

Investigational Site Number 3920002, Osaka

Investigational Site Number 3920003, Sapporo

Investigational Site Number 3920001, Yokohama

Investigational Site Number 8400007, Hato Rey

Investigational Site Number 7240005, Barcelona